Literature DB >> 29580577

Competing Risk of Death With End-Stage Renal Disease in Diabetic Kidney Disease.

Yue Jiang1, Jason P Fine1, Amy K Mottl2.   

Abstract

The concept of competing risks is particularly relevant to survival analyses of diabetic ESRD given the high likelihood of death prior to ESRD. Approaches such as Kaplan-Meier curves and Cox regression models operate on the assumption that there are no competing risks for the event of interest, yielding uninterpretable and generally biased estimates in the presence of competing risks. The cumulative incidence function and Fine-Gray regression are more appropriate methodologies for survival analysis when competing risks are present. We present an example taken from the Action to Control Cardiovascular Risk in Diabetes, a randomized trial of people with type 2 diabetes at high risk for cardiovascular disease. Participants were stratified according to baseline markers of kidney disease: (1) no kidney disease; (2) low estimated glomerular filtration rate; (3) microalbuminuria alone; and (4) macroalbuminuria. The macroalbuminuria group had the highest risk for ESRD and demonstrated the most marked difference between the Kaplan-Meier and cumulative incidence estimator. Cox and Fine-Gray regression models yielded similar risk estimates for baseline characteristics, with the exception of diabetes duration, which was significant in the Cox but not Fine-Gray model. We underscore the importance of competing risk methods, particularly when the competing risk is common, as is the case in diabetic kidney disease.
Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Competing risk; Death; Diabetic kidney disease; ESRD; Survival analysis

Mesh:

Year:  2018        PMID: 29580577     DOI: 10.1053/j.ackd.2018.01.008

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  5 in total

1.  The Combined Roles of Race/Ethnicity and Substance Use in Predicting Likelihood of Kidney Transplantation.

Authors:  Richelle N DeBlasio; Larissa Myaskovsky; Andrea F DiMartini; Emilee Croswell; Donna M Posluszny; Chethan Puttarajappa; Galen E Switzer; Ron Shapiro; Annette J DeVito Dabbs; Amit D Tevar; Sundaram Hariharan; Mary Amanda Dew
Journal:  Transplantation       Date:  2022-04-01       Impact factor: 5.385

2.  Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Authors:  Amy K Mottl; John B Buse; Faramarz Ismail-Beigi; Ronald J Sigal; Carolyn F Pedley; Vasilios Papademetriou; Debra L Simmons; Lois Katz; Josyf C Mychaleckyj; Timothy E Craven
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-25       Impact factor: 8.237

3.  Optimizing Decellularization Strategies for the Efficient Production of Whole Rat Kidney Scaffolds.

Authors:  Panagiotis Mallis; Charalampos Oikonomidis; Zetta Dimou; Catherine Stavropoulos-Giokas; Efstathios Michalopoulos; Michalis Katsimpoulas
Journal:  Tissue Eng Regen Med       Date:  2021-05-20       Impact factor: 4.169

4.  Fasting Glucose Variability as a Risk Indicator for End-Stage Kidney Disease in Patients with Diabetes: A Nationwide Population-Based Study.

Authors:  Da Young Lee; Jaeyoung Kim; Sanghyun Park; So Young Park; Ji Hee Yu; Ji A Seo; Nam Hoon Kim; Hye Jin Yoo; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Kyungdo Han; Nan Hee Kim
Journal:  J Clin Med       Date:  2021-12-18       Impact factor: 4.241

5.  Effect of depression on progression to end-stage renal disease or pre-end-stage renal disease death in advanced diabetic nephropathy: A prospective cohort study of the Diabetes Study from the Center of Tokyo Women's Medical University.

Authors:  Yu Horiba; Kaya Ishizawa; Keiko Takasaki; Junnosuke Miura; Tetsuya Babazono
Journal:  J Diabetes Investig       Date:  2021-07-17       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.